Patients should know whether a product is approved, investigational in a registered trial, or being marketed outside validated indications.
Evidence Boundary Brief
Unproven care
is not proof.
Regenerative medicine has legitimate science, but medical tourism can turn hope into a sales funnel. Verification must separate approved evidence, registered trials, unapproved products, and clinics selling cures without proof.
1FDA says approved stem-cell products in the U.S. are limited to blood-forming cells for specific uses
3CDC MMWR reported patients with M. abscessus infections after stem-cell treatments in Mexico
6-12+Months or longer can be required to treat some M. abscessus infections
0Amount of marketing language that can replace clinical evidence
Evidence boundary
Hope needs
a source record.
Patients seeking stem-cell, exosome, cancer, or transplant-related services abroad can be vulnerable because the offer is often framed as access to something unavailable at home. That is exactly when evidence standards need to rise.
Intrathecal, intravenous, joint, eye, and tissue injections carry different risks and require sterile product controls.
CDC has reported difficult-to-treat M. abscessus infections linked to stem-cell treatment tourism in Mexico.
Transplant tourism raises donor consent, trafficking, allocation, and legal concerns that go beyond ordinary clinic verification.
Verification standard
Do not sell
the unknown.
A serious page should not ridicule patients who are searching for help. It should protect them by asking direct questions: What is the product? Who manufactured it? What approval or trial status applies? What adverse events are known? What standard treatment might be delayed?
- Require product identity and source.
- Require approval or trial status.
- Require adverse-event disclosure.
- Require evidence that standard care is not being displaced.
Verification lens
Research becomes
a patient-safety rule.
Every incident, regulator warning, credential gap, and facility failure in this library is translated into a practical verification requirement before a surgeon profile earns trust.
Claims need records.
Degrees, licenses, specialty titles, facility authorization, and advertising claims are strongest when checked with the issuing source.
Evidence is not purchased.
A fee can support review work. It cannot buy favorable treatment, erase limits, or convert weak documentation into a verified finding.
The goal is earlier detection.
The point is to identify risks before travel: broker pressure, facility gaps, missing aftercare, testimonial manipulation, and unverifiable credentials.
Sources
Unproven therapy
source record.
Sources are listed so the page functions as a report, not an opinion piece. Media anecdotes are avoided unless supported by official or peer-reviewed records.
- FDA: patient information about regenerative medicine therapies
- FDA Regenerative Medicine 101: adverse events and unapproved products
- CDC MMWR: M. abscessus infections after stem-cell clinics in Mexico
- CDC EID: M. abscessus meningitis after stem-cell treatment tourism
- Declaration of Istanbul: organ trafficking and transplant tourism